Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once-weekly somapacitan or daily growth hormone.

Fumio OtsukaYutaka TakahashiShigeyuki TaharaYoshihisa OgawaMichael Højby RasmussenKoji Takano

Published in: Clinical endocrinology (2020)

Treatment in both groups was well tolerated, with no unexpected safety findings. Impact on adipose tissue was similar to somapacitan and daily GH in patients with AGHD. A short visual summary of our work is available at https://bit.ly/3946YNF.

Keyphrases

growth hormone
adipose tissue
physical activity
double blind
open label
placebo controlled
phase iii
high fat diet
insulin resistance
replacement therapy
phase ii
type diabetes
metabolic syndrome
smoking cessation